Results 191 to 200 of about 2,162 (261)

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies. [PDF]

CNS Drugs
Dzamko N.
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging. [PDF]

Fluids Barriers CNS
Pierobon Mays G, Hett K, Eisma J, McKnight CD, Elenberger J, Song AK, Considine C, Richerson WT, Han C, Stark A, Claassen DO, Donahue MJ.   +11 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan. [PDF]

Clin Auton Res
Kaufmann H, Palma JA, Millar Vernetti P, Kuijpers M, Nkrumah G, Kang UJ, Ma T, Betensky RA, Claassen DO, Vemuri P, Trujillo P, Siderowf A, Soto C, Feigin AS, Stebbins GT, Lindahl J, Qureshi I, Berger AK, Husnik M, Fanciulli A, Poewe W, Krismer F, Biaggioni I, Singer W, MuSyCA Working Group.   +24 more
europepmc   +1 more source

For the eye altering, alters the all

, 2015
De Scheerder, Marie-Angélique, Mahieu, Elien, Boey, Olivier, Vanuytsel, Johan, Bogaert, Anne-Marie   +4 more
openaire   +1 more source

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, EarlyView.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source

Talking across worlds: The ontological turn and communication in natural resource co-management with Indigenous communities. [PDF]

Prog Environ Geogr
Chew S.
europepmc   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

ATH434, a promising iron-targeting compound for treating iron regulation disorders. [PDF]

Metallomics
Pall AE, Bond S, Bailey DK, Stoj CS, Deschamps I, Huggins P, Parsons J, Bradbury MJ, Kosman DJ, Stemmler TL.   +9 more
europepmc   +1 more source